𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

✍ Scribed by Jin Li; Xinmin Zhao; Lei Chen; Haiyi Guo; Fangfang Lv; Ka Jia; Ke Yv; Fengqing Wang; Chuan Li; Jun Qian; Chunlei Zheng; Yunxia Zuo

Book ID
118726576
Publisher
BioMed Central
Year
2010
Tongue
English
Weight
547 KB
Volume
10
Category
Article
ISSN
1471-2407

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

YN968D1 is a novel and selective inhibit
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
✍ Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang LΓΌ; Yongping Xu; Jin πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 527 KB

Angiogenesis is an important process in cell development, especially in cancer. Vascular endothelial growth factor (VEGF) signaling is an important regulator of angiogenesis. Several therapies that act against VEGF signal transduction have been developed, including YN968D1, which is a potent inhibit

Vascular endothelial growth factor and v
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation
✍ Antonio Rueda; Oscar Cazorla; Lidia PΓ©rez; Martina Álvarez; Maximino Redondo; El πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 813 KB

## Abstract ## Background Vascular endothelial growth factor (VEGF) expression seems to be associated with worse overall survival in patients with head and neck squamous cell carcinoma. The purposes of this study were to assess the prognostic values of the immunohistochemical expression of VEGF an

Phase I Clinical and Pharmacokinetic Stu
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
✍ Strumberg, D. πŸ“‚ Article πŸ“… 2005 πŸ› American Society of Clinical Oncology 🌐 English βš– 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.